Atlas Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

Clinical trial NCT05654870 · TERMINATED

Trial details

NCT number
NCT05654870
Sponsor
Neurocrine Biosciences
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2023-01-05
Primary completion
2023-11-08
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.